Literature DB >> 18946735

Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.

Takeshi Tsuji1, Masato Asanuma, Ikuko Miyazaki, Ko Miyoshi, Norio Ogawa.   

Abstract

We examined changes in nuclear peroxisome proliferator-activated receptor gamma (PPAR gamma) in the striatum in methamphetamine (METH)-induced dopaminergic neurotoxicity, and also examined effects of treatment with drugs possessing PPAR gamma agonistic properties. The marked reduction of nuclear PPAR gamma-expressed cells was seen in the striatum 3 days after METH injections (4 mg/kg x 4, i.p. with 2-h interval). The reduction of dopamine transporter (DAT)-positive signals and PPAR gamma expression, and accumulation of activated microglial cells were significantly and dose-dependently attenuated by four injections of a nonsteroidal anti-inflammatory drug and a PPAR gamma ligand, ibuprofen (10 or 20 mg/kg x 4, s.c.) given 30 min prior to each METH injection, but not by either a low or high dose of aspirin. Either treatment of ibuprofen or aspirin, that showed no effects on METH-induced hyperthermia, significantly blocked the METH-induced striatal cyclooxygenase (COX) expression. Furthermore, the treatment of an intrinsic PPAR gamma ligand 15d-PG J2 also attenuated METH injections-induced reduction of striatal DAT. Therefore, the present study suggests the involvement of reduction of PPAR gamma expression in METH-induced neurotoxicity. Taken together with the previous report showing protective effects of other PPAR gamma ligand, these results imply that the protective effects of ibuprofen against METH-induced neurotoxicity may be based, in part, on its anti-inflammatory PPAR gamma agonistic properties, but not on its COX-inhibiting property or hypothermic effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18946735     DOI: 10.1007/s11064-008-9863-x

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

1.  Methamphetamine-induced neurotoxicity is attenuated in transgenic mice with a null mutation for interleukin-6.

Authors:  B Ladenheim; I N Krasnova; X Deng; J M Oyler; A Polettini; T H Moran; M A Huestis; J L Cadet
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

2.  Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?

Authors:  Masato Asanuma; Ikuko Miyazaki
Journal:  Exp Neurol       Date:  2007-05-18       Impact factor: 5.330

3.  Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin.

Authors:  M S Jaradat; B Wongsud; S Phornchirasilp; S M Rangwala; G Shams; M Sutton; K J Romstedt; D J Noonan; D R Feller
Journal:  Biochem Pharmacol       Date:  2001-12-15       Impact factor: 5.858

4.  Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase.

Authors:  S Z Imam; G D Newport; Y Itzhak; J L Cadet; F Islam; W Slikker; S F Ali
Journal:  J Neurochem       Date:  2001-02       Impact factor: 5.372

5.  Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.

Authors:  G P Lim; F Yang; T Chu; P Chen; W Beech; B Teter; T Tran; O Ubeda; K H Ashe; S A Frautschy; G M Cole
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

6.  Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine.

Authors:  Lin Zhang; Kiyoyuki Kitaichi; Yohei Fujimoto; Hironao Nakayama; Eiji Shimizu; Masaomi Iyo; Kenji Hashimoto
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-12       Impact factor: 5.067

7.  Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules.

Authors:  Ikuko Miyazaki; Masato Asanuma; Francisco J Diaz-Corrales; Masaya Fukuda; Kiyoyuki Kitaichi; Ko Miyoshi; Norio Ogawa
Journal:  FASEB J       Date:  2006-01-10       Impact factor: 5.191

Review 8.  Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.

Authors:  Masato Asanuma; Ikuko Miyazaki
Journal:  Expert Rev Neurother       Date:  2006-09       Impact factor: 4.618

9.  Methamphetamine-induced neurotoxicity is associated with increased striatal AP-1 DNA-binding activity in mice.

Authors:  P Sheng; B Ladenheim; T H Moran; X B Wang; J L Cadet
Journal:  Brain Res Mol Brain Res       Date:  1996-11

10.  Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus.

Authors:  T Yamaguchi; Y Kuraishi; M Minami; S Nakai; Y Hirai; M Satoh
Journal:  Neurosci Lett       Date:  1991-07-08       Impact factor: 3.046

View more
  11 in total

1.  Suppression of endogenous PPARγ increases vulnerability to methamphetamine-induced injury in mouse nigrostriatal dopaminergic pathway.

Authors:  Seong-Jin Yu; Mikko Airavaara; Hui Shen; Jenny Chou; Brandon K Harvey; Yun Wang
Journal:  Psychopharmacology (Berl)       Date:  2011-12-13       Impact factor: 4.530

Review 2.  Role of Mitochondria in Methamphetamine-Induced Dopaminergic Neurotoxicity: Involvement in Oxidative Stress, Neuroinflammation, and Pro-apoptosis-A Review.

Authors:  Eun-Joo Shin; Hai-Quyen Tran; Phuong-Tram Nguyen; Ji Hoon Jeong; Seung-Yeol Nah; Choon-Gon Jang; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Res       Date:  2017-06-07       Impact factor: 3.996

3.  Use of ibuprofen and risk of Parkinson disease.

Authors:  Xiang Gao; Honglei Chen; Michael A Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2011-03-02       Impact factor: 9.910

4.  Neuroprotective Effects of Anti-high Mobility Group Box-1 Monoclonal Antibody Against Methamphetamine-Induced Dopaminergic Neurotoxicity.

Authors:  Kaori Masai; Keita Kuroda; Nami Isooka; Ryo Kikuoka; Shinki Murakami; Sunao Kamimai; Dengli Wang; Keyue Liu; Ikuko Miyazaki; Masahiro Nishibori; Masato Asanuma
Journal:  Neurotox Res       Date:  2021-08-21       Impact factor: 3.911

Review 5.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 6.  Neuroinflammatory responses in Parkinson's disease: relevance of Ibuprofen in therapeutics.

Authors:  Ashish Singh; Pratibha Tripathi; Sarika Singh
Journal:  Inflammopharmacology       Date:  2020-10-14       Impact factor: 4.473

7.  Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.

Authors:  Ashish Singh; Pratibha Tripathi; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2015-12-12       Impact factor: 5.590

Review 8.  Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia.

Authors:  Rae R Matsumoto; Michael J Seminerio; Ryan C Turner; Matthew J Robson; Linda Nguyen; Diane B Miller; James P O'Callaghan
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

Review 9.  Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yeonggwang Hwang; Naveen Sharma; Duy-Khanh Dang; Bao-Trong Nguyen; Seung-Yeol Nah; Choon-Gon Jang; Guoying Bing; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2021-07-20       Impact factor: 4.946

10.  Chronic voluntary oral methamphetamine induces deficits in spatial learning and hippocampal protein kinase Mzeta with enhanced astrogliosis and cyclooxygenase-2 levels.

Authors:  Jorge A Avila; Roseanna M Zanca; Denis Shor; Nicholas Paleologos; Amber A Alliger; Maria E Figueiredo-Pereira; Peter A Serrano
Journal:  Heliyon       Date:  2018-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.